New directions in targeting protein kinases: Focusing upon true allosteric and bivalent inhibitors

Vandana Lamba, Indraneel Ghosh

Research output: Contribution to journalArticle

77 Citations (Scopus)

Abstract

Over the past decade, therapeutics that target subsets of the 518 human protein kinases have played a vital role in the fight against cancer. Protein kinases are typically targeted at the adenosine triphosphate (ATP) binding cleft by type I and II inhibitors, however, the high sequence and structural homology shared by protein kinases, especially at the ATP binding site, inherently leads to polypharmacology. In order to discover or design truly selective protein kinase inhibitors as both pharmacological reagents and safer therapeutic leads, new efforts are needed to target kinases outside the ATP cleft. Recent advances include the serendipitous discovery of type III inhibitors that bind a site proximal to the ATP pocket as well as the truly allosteric type IV inhibitors that target protein kinases distal to the substrate binding pocket. These new classes of inhibitors are often selective but usually display moderate affinities. In this review we will discuss the different classes of inhibitors with an emphasis on bisubstrate and bivalent inhibitors (type V) that combine different inhibitor classes. These inhibitors have the potential to couple the high affinity and potency of traditional active site targeted small molecule inhibitors with the selectivity of inhibitors that target the protein kinase surface outside ATP cleft.

Original languageEnglish (US)
Pages (from-to)2936-2945
Number of pages10
JournalCurrent Pharmaceutical Design
Volume18
Issue number20
StatePublished - Jul 2012

Fingerprint

Protein Kinases
Adenosine Triphosphate
Protein Kinase Inhibitors
Polypharmacology
Sequence Homology
Catalytic Domain
Phosphotransferases
Binding Sites
Direction compound
Pharmacology
Therapeutics
Neoplasms

Keywords

  • Bisubstrate
  • Bivalent
  • Inhibitors
  • Protein kinase

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology

Cite this

New directions in targeting protein kinases : Focusing upon true allosteric and bivalent inhibitors. / Lamba, Vandana; Ghosh, Indraneel.

In: Current Pharmaceutical Design, Vol. 18, No. 20, 07.2012, p. 2936-2945.

Research output: Contribution to journalArticle

@article{34ba8ef404604d69ae4054f3d9ba0ee2,
title = "New directions in targeting protein kinases: Focusing upon true allosteric and bivalent inhibitors",
abstract = "Over the past decade, therapeutics that target subsets of the 518 human protein kinases have played a vital role in the fight against cancer. Protein kinases are typically targeted at the adenosine triphosphate (ATP) binding cleft by type I and II inhibitors, however, the high sequence and structural homology shared by protein kinases, especially at the ATP binding site, inherently leads to polypharmacology. In order to discover or design truly selective protein kinase inhibitors as both pharmacological reagents and safer therapeutic leads, new efforts are needed to target kinases outside the ATP cleft. Recent advances include the serendipitous discovery of type III inhibitors that bind a site proximal to the ATP pocket as well as the truly allosteric type IV inhibitors that target protein kinases distal to the substrate binding pocket. These new classes of inhibitors are often selective but usually display moderate affinities. In this review we will discuss the different classes of inhibitors with an emphasis on bisubstrate and bivalent inhibitors (type V) that combine different inhibitor classes. These inhibitors have the potential to couple the high affinity and potency of traditional active site targeted small molecule inhibitors with the selectivity of inhibitors that target the protein kinase surface outside ATP cleft.",
keywords = "Bisubstrate, Bivalent, Inhibitors, Protein kinase",
author = "Vandana Lamba and Indraneel Ghosh",
year = "2012",
month = "7",
language = "English (US)",
volume = "18",
pages = "2936--2945",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "20",

}

TY - JOUR

T1 - New directions in targeting protein kinases

T2 - Focusing upon true allosteric and bivalent inhibitors

AU - Lamba, Vandana

AU - Ghosh, Indraneel

PY - 2012/7

Y1 - 2012/7

N2 - Over the past decade, therapeutics that target subsets of the 518 human protein kinases have played a vital role in the fight against cancer. Protein kinases are typically targeted at the adenosine triphosphate (ATP) binding cleft by type I and II inhibitors, however, the high sequence and structural homology shared by protein kinases, especially at the ATP binding site, inherently leads to polypharmacology. In order to discover or design truly selective protein kinase inhibitors as both pharmacological reagents and safer therapeutic leads, new efforts are needed to target kinases outside the ATP cleft. Recent advances include the serendipitous discovery of type III inhibitors that bind a site proximal to the ATP pocket as well as the truly allosteric type IV inhibitors that target protein kinases distal to the substrate binding pocket. These new classes of inhibitors are often selective but usually display moderate affinities. In this review we will discuss the different classes of inhibitors with an emphasis on bisubstrate and bivalent inhibitors (type V) that combine different inhibitor classes. These inhibitors have the potential to couple the high affinity and potency of traditional active site targeted small molecule inhibitors with the selectivity of inhibitors that target the protein kinase surface outside ATP cleft.

AB - Over the past decade, therapeutics that target subsets of the 518 human protein kinases have played a vital role in the fight against cancer. Protein kinases are typically targeted at the adenosine triphosphate (ATP) binding cleft by type I and II inhibitors, however, the high sequence and structural homology shared by protein kinases, especially at the ATP binding site, inherently leads to polypharmacology. In order to discover or design truly selective protein kinase inhibitors as both pharmacological reagents and safer therapeutic leads, new efforts are needed to target kinases outside the ATP cleft. Recent advances include the serendipitous discovery of type III inhibitors that bind a site proximal to the ATP pocket as well as the truly allosteric type IV inhibitors that target protein kinases distal to the substrate binding pocket. These new classes of inhibitors are often selective but usually display moderate affinities. In this review we will discuss the different classes of inhibitors with an emphasis on bisubstrate and bivalent inhibitors (type V) that combine different inhibitor classes. These inhibitors have the potential to couple the high affinity and potency of traditional active site targeted small molecule inhibitors with the selectivity of inhibitors that target the protein kinase surface outside ATP cleft.

KW - Bisubstrate

KW - Bivalent

KW - Inhibitors

KW - Protein kinase

UR - http://www.scopus.com/inward/record.url?scp=84861722034&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861722034&partnerID=8YFLogxK

M3 - Article

C2 - 22571662

AN - SCOPUS:84861722034

VL - 18

SP - 2936

EP - 2945

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 20

ER -